Become a Member

Topic Archives: Cubist Pharmaceuticals (CBST)

  • What’s Bonner’s “FDA Fast Tracks $6.8 Billion Miracle Antibiotic” pitch about?

    Checking into Jeff Brown's "July 1st Approval" teaser pitch -- he says that " I believe this tiny company is sitting on the biggest medical breakthrough in over three decades. Possibly since the discovery of penicillin in 1928."

    59 Comments Read More
  • What’s the “Miracle on Mount Ararat” Drug?

    What's teased as the solution to "The Next Pandemic" by Bill Patalon?

    18 Comments Read More
  • The 2015 Stock Gumshoe Biotechnology Awards Show!

    THE YEAR THAT WAS

    984 Comments Read More
  • Need to Know: Special Update on Achaogen

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions.] If you get infected with CRE in your blood, your lungs, your urine, or your biliary system, what is your chance of […]

    Leave a comment Read More
  • What’s “Stansberry Venture #1?”

    Dave Lashmet: "The Death of Cancer May be MUCH Closer Than You Think and One Tiny Company is Poised to Deal the Fatal Blow"

    31 Comments Read More
  • written by reader Special Update on Cellceutix

    [ed. note: Dr. KSS writes about biotech stocks for the Irregulars. He has agreed to our trading restrictions, but he chooses his own topics and his words and thoughts are his own] According to new SEC filings, Cellceutix President, co-founder and Chief Scientific Officer Krishna Menon has recently settled what should probably be regarded as […]

    308 Comments Read More
  • written by reader Oxidation for Health…Physical and Fiscal

    [Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]

    1,353 Comments Read More
  • written by reader Antibiotics Don’t Get No Respect, But You Can Still Profit From Them

    DR. KSS TAKES ON ANTIBIOTICS

    588 Comments Read More
  • written by reader How Worried Should We Be About Antibiotic-Resistant Pathogens?

    Musings on malevolent microorganisms from our favorite medical writer, Doc Gumshoe

    38 Comments Read More
  • Killing the Superbug: “Owning this stock is like holding a winning lottery ticket” (Skousen)

    Mark Skousen, who is one of those Ph.D-type doctors (economics) and thankfully doesn’t always insist on being called Dr. Skousen (yes, we’re looking at you Dr. Leeb), is pitching a health care stock today as a teaser for his Forecasts and Strategies newsletter. And like some folks we’ve heard from in the past, he’s teasing […]

    28 Comments Read More
  • Comments

  • Achaogen Appoints Halley Gilbert to Its Board of Directors$AKAO Achaogen, Inc. a clinical-stage biopharmaceutical co...

  • Today I received (yet another) spiel today about how Mark Skousen's oft-touted Elite "SS-4 Income Stream" could make me ...

  • Glenn, I think that the devil (in this case the angels) is/are in the details. The Sec filing regarding the $ZFGN direct...

  • AKAO has a Cubist xSVP on Board- :-) Long. Thanks Dr. KSS! Achaogen Announces Appointment of Greg Stea to Board of ...

  • Like the hire for Trevena (TRVN)with her pain medicine and acute heart failure background with Merck.Trevena Appoint...

  • "One more thing!" -- Colombo I received this over the weekend from S & A Master Series:The four new gram-negat...

  • Following Fierce Biotech article published today rekindles the fire re rumors of CBST as Big Pharma merger/acquisition t...

  • This from CTIX this morning.Exciting times ahead.I think management is executing nicely.Cellceutix Believes Brilacid...

  • AKAO news Achaogen (NASDAQ:AKAO) appoints Ian Friedland, M.D., as its Chief Medical Officer. He joins the company from...

  • Dovetailing into JZ's mantra of buying Big Pharma, Mathew Carr from the Oxford Emerging Trends Trader (a VIP service new...

  • Oops, didn't dig deep enough. Trius was bought out in Sept. 2013 by Cubist Pharmaceuticals, which is trading ~$76....

  • This from 5/26/11: BOSTON (MarketWatch) -- Shares of Cambridge, Mass.-based Cubist Pharmaceuticals were up 6% in morning...

  • Cubist Pharmaceuticals, the drug is cubicin CBST ...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info